---
title: "Johnson & Johnson says Phase 3 trial shows Caplyta cuts bipolar I mania symptoms by Week 3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299638423.md"
description: "Johnson & Johnson reported positive Phase 3 trial results for Caplyta, demonstrating rapid and sustained reduction of bipolar I mania symptoms by Week 3 compared to placebo. Although currently approved only for bipolar depression and schizophrenia, these findings support a potential indication expansion. A second pivotal Phase 3 study for this specific use has concluded with analysis underway."
datetime: "2026-09-21T12:01:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299638423.md)
  - [en](https://longbridge.com/en/news/299638423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299638423.md)
generator: "portal-rs"
---

# Johnson & Johnson says Phase 3 trial shows Caplyta cuts bipolar I mania symptoms by Week 3

-   Johnson & Johnson reported positive topline Phase 3 results for Caplyta in acute manic episodes tied to bipolar I disorder. \* Findings were already presented in a late-breaking session at the 2026 Psych Congress Annual Meeting. \* The trial showed rapid, sustained symptom improvement versus placebo, supporting a potential expansion beyond bipolar depression and schizophrenia. \* Caplyta is not approved for bipolar I mania; a second pivotal Phase 3 study has finished with analysis underway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210800PR\_NEWS\_USPR\_\_\_\_\_CG51607) on September 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition](https://longbridge.com/en/news/298947604.md)
- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [LIVE MARKETS-Wall Street's AI math doesn't add up](https://longbridge.com/en/news/300462731.md)
- [What's Going On With Oracle Stock Tuesday?](https://longbridge.com/en/news/300437295.md)
- [Oracle Fusion Claw the new grab for fully autonomous agentic AI in ERP](https://longbridge.com/en/news/300498928.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**